AU2005222707B2 - Control of feeding behavior by changing neuronal energy balance - Google Patents

Control of feeding behavior by changing neuronal energy balance Download PDF

Info

Publication number
AU2005222707B2
AU2005222707B2 AU2005222707A AU2005222707A AU2005222707B2 AU 2005222707 B2 AU2005222707 B2 AU 2005222707B2 AU 2005222707 A AU2005222707 A AU 2005222707A AU 2005222707 A AU2005222707 A AU 2005222707A AU 2005222707 B2 AU2005222707 B2 AU 2005222707B2
Authority
AU
Australia
Prior art keywords
ampk
aicar
hypothalamic
food intake
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005222707A
Other languages
English (en)
Other versions
AU2005222707A1 (en
Inventor
Eun-Kyoung Kim
Francis P. Kuhajda
Leslie E. Landree
Timothy H. Moran
Gabrielle V. Ronnett
Jagan N. Thupari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Fasgen LLC
Original Assignee
Johns Hopkins University
Fasgen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Fasgen LLC filed Critical Johns Hopkins University
Publication of AU2005222707A1 publication Critical patent/AU2005222707A1/en
Application granted granted Critical
Publication of AU2005222707B2 publication Critical patent/AU2005222707B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005222707A 2004-03-18 2005-03-18 Control of feeding behavior by changing neuronal energy balance Ceased AU2005222707B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55422804P 2004-03-18 2004-03-18
US60/554,228 2004-03-18
PCT/US2005/009069 WO2005089773A1 (en) 2004-03-18 2005-03-18 Control of feeding behavior by changing neuronal energy balance

Publications (2)

Publication Number Publication Date
AU2005222707A1 AU2005222707A1 (en) 2005-09-29
AU2005222707B2 true AU2005222707B2 (en) 2010-06-17

Family

ID=34993435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005222707A Ceased AU2005222707B2 (en) 2004-03-18 2005-03-18 Control of feeding behavior by changing neuronal energy balance

Country Status (6)

Country Link
US (1) US20080119548A1 (enExample)
EP (1) EP1732572A4 (enExample)
JP (1) JP2007529549A (enExample)
AU (1) AU2005222707B2 (enExample)
CA (1) CA2560035A1 (enExample)
WO (1) WO2005089773A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100016016A (ko) * 2007-03-30 2010-02-12 산토리 홀딩스 가부시키가이샤 교감 신경 활동 항진 작용을 갖는 의약 조성물 또는 음식물
JP5807919B2 (ja) * 2013-07-31 2015-11-10 大学共同利用機関法人自然科学研究機構 糖尿病による代謝異常を改善するための組成物
BR112024002354A2 (pt) * 2021-08-06 2024-04-30 Centre Nat Rech Scient Populações de pequenas vesículas extracelulares para uso no tratamento de obesidade
EP4137148A1 (en) * 2021-08-17 2023-02-22 Universidade de Santiago de Compostela Small extracellular vesicles expressing a dominant negative ampk alpha 1 mutant for use in the treatment of obesity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010449A1 (en) * 1999-08-09 2001-02-15 Trustees Of Boston University Method of maintaining vascular integrity using aicar (5-amino-4-imidazole riboside) and related compounds
WO2001093873A1 (en) * 2000-06-06 2001-12-13 Trustees Of Boston University Use of aicar and related compounds
WO2002009726A1 (en) * 2000-07-31 2002-02-07 Trustees Of Boston University Methods of treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
KR20030016228A (ko) * 2000-02-16 2003-02-26 존스 홉킨스 유니버시티 스쿨 오브 메디슨 신경펩티드 ｙ 농도의 감소에 의해 유도되는 체중 감량
US20030212013A1 (en) * 2001-06-14 2003-11-13 Winder William W Use of amp kinase activators for treatment type 2 diabetes and insulin resistance
US20050143467A1 (en) * 2002-02-08 2005-06-30 The Johns Hopkins University School Of Medicine Licensing And Technology Development Stimulation of cpt-1 as a means to reduce weight

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010449A1 (en) * 1999-08-09 2001-02-15 Trustees Of Boston University Method of maintaining vascular integrity using aicar (5-amino-4-imidazole riboside) and related compounds
WO2001093873A1 (en) * 2000-06-06 2001-12-13 Trustees Of Boston University Use of aicar and related compounds
WO2002009726A1 (en) * 2000-07-31 2002-02-07 Trustees Of Boston University Methods of treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
32nd meeting of the Soc for Neuroscience 02-07 Nov 2002, abstract 581.4 *
33rd meeting of the Soc for Neuroscience 08-12 Nov 2003, abstract 193.3 *
Diabetes 51, 3196-3201, 2002 *
J Bioi Chem 279(5), 3817-3824, 30 Jan 2004 *
Nature medicine 9(5) 483-485, 2003 *
PNAS 100(10) 5628-5633, 2003 *
PNAS 100(22) 12624-12629,2003 *

Also Published As

Publication number Publication date
US20080119548A1 (en) 2008-05-22
AU2005222707A1 (en) 2005-09-29
CA2560035A1 (en) 2005-09-29
EP1732572A4 (en) 2007-04-18
JP2007529549A (ja) 2007-10-25
EP1732572A1 (en) 2006-12-20
WO2005089773A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
Landree et al. C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism
Aatsinki et al. Metformin induces PGC‐1α expression and selectively affects hepatic PGC‐1α functions
Buler et al. SIRT5 is under the control of PGC‐1α and AMPK and is involved in regulation of mitochondrial energy metabolism
Meur et al. Tonic activation of NMDA receptors by ambient glutamate of non‐synaptic origin in the rat hippocampus
Mitsikostas et al. Non‐NMDA glutamate receptors modulate capsaicin induced c‐fos expression within trigeminal nucleus caudalis
Ding et al. Sensitization of ventral tegmental area dopamine neurons to the stimulating effects of ethanol
US7022484B2 (en) Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
Nguyen et al. Propionate increases neuronal histone acetylation, but is metabolized oxidatively by glia. Relevance for propionic acidemia
Cai et al. Zinc neurotoxicity is dependent on intracellular NAD+ levels and the sirtuin pathway
CA2339218C (en) Methods and compositions for increasing insulin sensitivity
Rewal et al. Alpha4 subunit‐containing GABAA receptors in the accumbens shell contribute to the reinforcing effects of alcohol
Pil Hwang et al. 3‐Caffeoyl, 4‐dihydrocaffeoylquinic acid from S alicornia herbacea attenuates high glucose‐induced hepatic lipogenesis in human H ep G 2 cells through activation of the liver kinase B 1 and silent information regulator T 1/AMPK‐dependent pathway
AU2013266086A1 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
Biswas et al. Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through control of cell heme allocation by nitric oxide
Oguri et al. Tetrahydrobiopterin activates brown adipose tissue and regulates systemic energy metabolism
Kimura et al. Protein kinase CK2 modulates synaptic plasticity by modification of synaptic NMDA receptors in the hippocampus
Rosenberg et al. Regulation of cytochrome P450 in cultured human colonic cells
AU2005222707B2 (en) Control of feeding behavior by changing neuronal energy balance
Oshima et al. Evidence for organic cation transporter-mediated metformin transport and 5′-adenosine monophosphate-activated protein kinase activation in rat skeletal muscles
Pei‐Yuan et al. Overexpression of Axl reverses endothelial cells dysfunction in high glucose and hypoxia
Nho et al. β1-Integrin-collagen interaction suppresses FoxO3a by the coordination of Akt and PP2A
Forget et al. Impact of basic FGF expression in astrocytes on dopamine neuron synaptic function and development
Sergeeva et al. GABAA‐receptor modification in taurine transporter knockout mice causes striatal disinhibition
Young et al. An astrocyte toxin influences the pattern of breathing and the ventilatory response to hypercapnia in neonatal rats
Salgado et al. GKRP-dependent modulation of feeding behavior by tanycyte-released monocarboxylates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired